Home/Pipeline/MT-304

MT-304

Breast Cancer

Phase 1Active

Key Facts

Indication

Breast Cancer

Phase

Phase 1

Status

Active

Company

Create Medicines

About Create Medicines

Create Medicines is developing a novel class of immunotherapies via its proprietary in vivo CAR platform, which uses mRNA-LNP formulations to program multiple immune cell types directly in the body. This approach seeks to overcome the manufacturing complexity, cost, and time constraints of ex vivo cell therapies. The company has generated first-in-human clinical data confirming mechanism of action and is advancing a pipeline with programs in Phase 1 and Phase 2 for solid tumors and hematologic malignancies. Founded in 2021 and based in Boston, CREATE is a private, pre-revenue company positioning itself at the forefront of scalable, off-the-shelf cell therapy.

View full company profile

Therapeutic Areas

Oncology Autoimmune Diseases Fibrosis

Other Breast Cancer Drugs

Drug	Company	Phase	Status
Antifibrotic Therapy Program	MeCo Diagnostics	Pre-clinical	Active
inPROBE for HER2	SDS Optic	Clinical Investigation	Completed (March 2023)
ACT‑BC1	Anthrocell	Preclinical	Active
APA-1000 Breast Thermotherapy System	Medifocus	Phase III	Pivotal Trial Approved (IDE/ITA)
Early‑Detection Breast Cancer Screening	Karkinos Healthcare	Market	Active
Unnamed Breast Cancer Program	Click Therapeutics	Pilot/Phase 2	Active
Lerociclib (Lerocliclib)	Chemogenics BioPharma	Phase 3	Completed Phase 3, awaiting FDA approval
AT-017	Asieris Pharmaceuticals	Not Specified	Active
CDK2 inhibitor	Acellera	Pre-clinical	Hit Identification
NP-G2-044	Novita Pharmaceuticals	Phase 2a	Active (subset)
Maveropepimut-S (MVP-S)	BioVaxys	Clinical Evaluation	Active
Cannabics® BRST-33	CNBX Pharmaceuticals	Discovery	In vitro POC